Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07317271 · ClinicalTrials.gov registry record · NA

VR-PMR for Post-Burn Symptoms

A NA study of Anxiety and Depressive Symptoms, sponsored by Johns Hopkins University.

Recruiting
Registry status
NA
Development phase
34
Enrollment target
1
Study location

NCT07317271: Recruiting NA study of Anxiety and Depressive Symptoms, sponsored by Johns Hopkins University.

NCT07317271 is a NA study of Anxiety and Depressive Symptoms that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 34 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07317271, a NA study of Anxiety and Depressive Symptoms, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
NA
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Primary Outcome

Pain will be measured using the the Numeric Rating Scale (NRS). Scale range 0-10, higher score worse pain severity.

Conditions Studied

Anxiety Depressive Symptoms Sleep Disturbance Virtual Reality Pruritus Burn Injury Burn Fatigue Symptom Chronic Pain Following Thermal Burn Injury Non-Pharmacological Interventions

Interventions

  • BEHAVIORAL Virtual Reality-Enhanced Progressive Muscle Relaxation
  • BEHAVIORAL Standard Progressive Muscle Relaxation

Study Locations (1)

Maryland

  • Johns Hopkins Bayview Medical Center - Baltimore

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2026-02-27
Est. Completion 2026-12
Phase NA
Johns Hopkins University

1,448 total trials

What NCT07317271 shows while recruiting

NCT07317271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (92% lower).

The record links to 10 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Virtual Reality-Enhanced Progressive Muscle Relaxation is the first listed.

NCT07317271 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT07317271 about?

NCT07317271 is a clinical study titled "VR-PMR for Post-Burn Symptoms". The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to...

What is the current status of trial NCT07317271?

This trial is currently recruiting. It is a NA study. The enrollment target is 34 participants. The study started on 2026-02-27. Estimated completion is 2026-12.

What conditions does trial NCT07317271 study?

This clinical trial studies the following conditions: Anxiety, Depressive Symptoms, Sleep Disturbance, Virtual Reality, Pruritus.

What interventions are being tested in trial NCT07317271?

The interventions under investigation include: Virtual Reality-Enhanced Progressive Muscle Relaxation (BEHAVIORAL), Standard Progressive Muscle Relaxation (BEHAVIORAL).

Who is sponsoring clinical trial NCT07317271?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07317271 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07317271's enrollment target sits among peer trials

34 293rd of 364 higher than 72 of 364 other Anxiety trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07317271

Source: ClinicalTrials.gov NCT07317271, the US trial registry maintained by the National Library of Medicine. NCT07317271 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.